Bone Health and Denosumab Discontinuation in Oncology Populations

被引：2
|
作者：
Cheung, Yee-Ming Melody [1 ,2 ,3 ]
Morgans, Alicia [2 ,4 ]
Hamnvik, Ole-Petter Riksfjord [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, 221 Longwood Ave,RFB 2, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Melbourne, Austin Hosp, Dept Med, Endocrine Unit, Melbourne, Vic, Australia
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
ONCOLOGIST | 2022年 / 27卷 / 12期
关键词：
bone health; cancer; denosumab discontinuation; multiple vertebral fractures; rebound phenomenon; ZOLEDRONIC ACID; MINERAL DENSITY; BREAST-CANCER; VERTEBRAL FRACTURES; PROSTATE-CANCER; DOUBLE-BLIND; POSITION STATEMENT; METASTASES; PREVENTION; THERAPY;
D O I：
10.1093/oncolo/oyac213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Managing bone health after denosumab cessation is a commonly encountered challenge. Although the "rebound phenomenon" is generally recognized by endocrinologists in the context of osteoporosis, it is not as widely understood in the context of bone metastases and cancer. This commentary reviews the evidence on the efficacy and safety of various bone health agents in mitigating the "rebound phenomenon" in cancer populations.
引用
收藏
页码：998 / 1003
页数：6
相关论文
共 50 条
  • [41] Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
    Teerapat Tutaworn
    Jeri W. Nieves
    Zhaorui Wang
    Justin E. Levin
    Jae E. Yoo
    Joseph M. Lane
    Osteoporosis International, 2023, 34 : 573 - 584
  • [42] CAN WE AVOID THE LOSS OF BONE MINERAL DENSITY ONE YEAR AFTER DENOSUMAB DISCONTINUATION? THE REOLAUS BONE PROJECT
    Liebich, G.
    Stoll, D.
    Gonzalez-Rodriguez, E.
    Hans, D.
    Lamy, O.
    Aubry-Rozier, B.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S706 - S707
  • [43] Can we avoid the loss of bone mineral density one year after denosumab discontinuation? The ReoLaus Bone Project
    Liebich, G.
    Stoll, D.
    Gonzalez-Rodriguez, E.
    Hans, D.
    Lamy, O.
    Aubry-Rozier, B.
    SWISS MEDICAL WEEKLY, 2019, : 9S - 9S
  • [44] CAN WE AVOID THE LOSS OF BONE MINERAL DENSITY ONE YEAR AFTER DENOSUMAB DISCONTINUATION? THE REOLAUS BONE PROJECT
    Aubry-Rozier, Berengere
    Liebich, Giovanni
    Stoll, Delphine
    Gonzalez-Rodriguez, Elena
    Hans, Didier
    Lamy, Olivier
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 115 - 115
  • [45] Multiple vertebral fractures after denosumab discontinuation
    Morel, A.
    Laugier, D.
    Azzouz, B.
    Lepoix, E.
    Trenque, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 189 - 189
  • [46] Prevention and Management of Denosumab Discontinuation Rebound Fractures
    Jain, Sumeet
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2024, 53 (04) : 559 - 583
  • [47] Clinical vertebral fractures following denosumab discontinuation
    Polyzos, Stergios A.
    Terpos, Evangelos
    ENDOCRINE, 2016, 54 (01) : 271 - 272
  • [48] Underestimation of Vertebral Fractures After Denosumab Discontinuation
    Lamy, Olivier
    Gonzalez-Rodriguez, Elena
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (03) : 547 - 547
  • [49] Clinical vertebral fractures following denosumab discontinuation
    Stergios A. Polyzos
    Evangelos Terpos
    Endocrine, 2016, 54 : 271 - 272
  • [50] Multiple vertebral fractures following denosumab discontinuation
    Buttazzoni, M.
    Galich, A. M.
    BONE, 2017, 105 : 304 - 304
12345